Observations following discontinuation of long-term denosumab therapy.

ABSTRACT: Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered.

Introduction

This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study.

Methods

During the observational year, patients received osteoporosis management at the discretion of their physician and returned to the clinic for BMD assessment and completion of an osteoporosis management questionnaire. Incidence of serious adverse events and fractu

SUBMITTER: McClung MR 

PROVIDER: S-EPMC5391373 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature